MedicaMetrix
Invest in the Future of Prostate Health
Overview
Raised: $581,950
Total Commitments ($USD)
Dalmore Group
09/12/2021
Not Provided
$250
Equity - Common
Series B
RegA+
$5.00
$20,000,000
Rolling Commitments ($USD)
11/29/2022
$1,341
13
2020
Healthcare & Pharmaceuticals
HealthTech
B2B
Medium
High
Balance Sheet
|
Cash and Cash Equivalents |
$2,729,996 |
|
Investment Securities |
$0 |
|
Total Investments |
$0 |
|
Accounts and Notes Receivable |
$88,000 |
|
Loans |
$0 |
|
Property, Plant and Equipment (PP&E) |
$11,400 |
|
Property and Equipment |
$0 |
| Total Assets |
$2,829,752 |
|
Accounts Payable & Accrued Liabilities |
$424,699 |
|
Policy Liabilities and Accruals |
$0 |
|
Deposits |
$0 |
|
Long Term Debt |
$0 |
|
Total Liabilities |
$424,699 |
|
Total Stockholders' Equity |
$2,405,053 |
| Total Liabilities and Equity |
$2,829,752 |
Statement of Comprehensive Income Information
|
Total Revenues |
$0 |
|
Total Interest Income |
$0 |
|
Costs & Expenses Applicable to Rev |
$1,017,987 |
|
Total Interest Expenses |
$0 |
|
Depreciation and Amortization |
$1,330 |
| Net Income |
$-1,017,987 |
|
Earnings Per Share - Basic |
$-0.10 |
|
Earnings Per Share - Diluted |
$-0.10 |
Upgrade to gain access
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
